TMS for Parkinson's Disease Apathy

(PDTMSAPATHY Trial)

Recruiting at 1 trial location

Overseen By Monica Coudurier

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of North Carolina, Chapel Hill

Must be taking: Dopaminergic, SSRIs, Stimulants

Must not be taking: Anti-dopaminergic

Disqualifiers: Dementia, Epilepsy, Brain surgery, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 3

Duration: 6 weeks

60 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how a non-invasive treatment called transcranial magnetic stimulation (TMS) might address motivation problems, known as apathy, in people with Parkinson's Disease. Researchers aim to determine if TMS can enhance task performance and if a link exists between brain signals and apathy. Participants will receive TMS at two different brain sites to identify which site might be more effective. Suitable candidates for this trial are individuals who have experienced Parkinson's Disease symptoms for at least five years and are on stable medication. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new insights and treatments for Parkinson's Disease.

Will I have to stop taking my current medications?

No, you will not have to stop taking your current medications. Participants must be stable on their Parkinson's medication and any other medications that may influence apathy for at least 4 weeks before the study and remain stable throughout the study.

What prior data suggests that transcranial magnetic stimulation (TMS) is safe for treating apathy in Parkinson's Disease?

Research has shown that transcranial magnetic stimulation (TMS) is generally safe for people with Parkinson's Disease. In studies, researchers used TMS on Parkinson's patients without major risks. Some patients experienced mild to moderate improvements in movement skills. TMS uses magnets to alter brain activity and has already proven helpful in treating depression and other mental health issues. Most people tolerate TMS well, but as with any treatment, monitoring for side effects is important. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Transcranial Magnetic Stimulation (TMS) is unique because it offers a non-invasive way to potentially alleviate apathy in Parkinson's disease by targeting specific brain regions like the medial prefrontal cortex. Unlike traditional treatments such as medications that often focus on dopamine replacement, TMS uses magnetic fields to stimulate nerve cells, which might address symptoms without the need for drugs and their side effects. Researchers are excited about TMS as it could offer a more direct and safer approach to managing apathy in Parkinson's patients, improving their quality of life with minimal intervention.

What evidence suggests that TMS is effective for treating apathy in Parkinson's Disease?

Research has shown that transcranial magnetic stimulation (TMS) can alleviate various symptoms of Parkinson's Disease. Studies have found that TMS improves movement problems and reduces depression in people with Parkinson's. Although these studies focus on different symptoms, they suggest that TMS might also address apathy, which refers to a lack of motivation. This trial will specifically test whether targeting certain brain areas with TMS can enhance motivation in people with Parkinson's. Participants will undergo TMS targeting either the medial prefrontal cortex or a control site, with a 3-week washout period between treatments, to evaluate its effects on motivation. ^{6 7 8 9 10}

Who Is on the Research Team?

Miriam Sklerov, MD

Principal Investigator

University of North Carolina, Chapel Hill

Are You a Good Fit for This Trial?

This trial is for Parkinson's Disease patients who've had symptoms for at least 5 years, are on stable dopaminergic medication, and can consent in English. Women must be postmenopausal or use contraception. Excluded are those with dementia, epilepsy, brain surgery history, metal implants like pacemakers or deep brain stimulators, severe tremor affecting EEG readings, other causes of parkinsonism or CNS diseases.

Inclusion Criteria

I can understand and consent to the study in English.

I am a woman who has not had a period in over 12 months or will use birth control during the study.

I have been diagnosed with Parkinson's Disease.

Exclusion Criteria

Presence of dementia (Montreal Cognitive Assessment (MoCA) score < 21)

Inability to provide informed consent

I cannot perform certain physical tasks as determined in a test.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-3 hours

1 visit (in-person)

Treatment

Participants receive transcranial magnetic stimulation (TMS) at two different sites with a 3-week washout period between sessions

6 weeks

2 visits (in-person)

Follow-up

Participants are monitored for changes in goal-directed behavior and reward evaluation after TMS

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Transcranial Magnetic Stimulation (TMS)

Trial Overview

The study tests if Transcranial Magnetic Stimulation (TMS) affects motivation in Parkinson's patients by comparing the effects of stimulating two different brain areas. Participants will do tasks to measure effort and have their brain activity recorded before and after TMS sessions at both sites.

How Is the Trial Designed?

Group I: Medial Prefrontal Cortex - Control Site Experimental Treatment 1 Intervention

Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the control site.

Group II: Control Site - Medial Prefrontal Cortex Experimental Treatment 1 Intervention

Participants first undergo transcranial magnetic stimulation to the control site. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex.

Transcranial Magnetic Stimulation (TMS) is already approved in United States, European Union for the following indications:

Approved in United States as Transcranial Magnetic Stimulation (TMS) for:

• Major Depressive Disorder (MDD)
• Obsessive-Compulsive Disorder (OCD)
• Migraine Headache Symptoms

Approved in European Union as Transcranial Magnetic Stimulation (TMS) for:

• Major Depressive Disorder (MDD)
• Obsessive-Compulsive Disorder (OCD)

Who Is Running the Clinical Trial?

University of North Carolina, Chapel Hill

Lead Sponsor

Trials

1,588

Recruited

4,364,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+

Published Research Related to This Trial

Theta-burst transcranial magnetic stimulation (TBS) is safe and well tolerated in patients with major depression, based on a study involving 33 participants over 10 consecutive days.

The study suggests that TBS may have antidepressant effects, and increasing stimulation parameters does not lead to more side effects, potentially enhancing its therapeutic benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. Chistyakov, AV., Rubicsek, O., Kaplan, B., et al.[2019]

Repetitive transcranial magnetic stimulation (rTMS) has gained popularity for its ability to modulate brain activity, but safety considerations are crucial, especially with the recent updates to safety guidelines published in 2021.

The guidelines emphasize the importance of screening for risks, monitoring for adverse events, and specific safety measures when using rTMS, particularly in patients with conditions like stroke and traumatic brain injury.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety Review for Clinical Application of Repetitive Transcranial Magnetic Stimulation. Kim, WS., Paik, NJ.[2023]

A review of 84 single pulse and paired-pulse TMS studies with 1091 Parkinson's disease patients, and 77 repetitive TMS studies with 1137 patients, found a very low risk of adverse events, with no seizures reported.

The overall risk of adverse events from rTMS was 0.040 per patient, with common side effects being mild and transient, such as headaches and scalp pain, indicating that TMS is generally safe for Parkinson's patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature. Vonloh, M., Chen, R., Kluger, B.[2021]

In a study involving 6 patients with Parkinson's disease and 10 normal controls, repetitive transcranial magnetic stimulation (rTMS) significantly improved choice reaction time and movement time in patients without affecting their error rate, suggesting enhanced motor function.

The rTMS treatment also improved performance on a grooved peg-board test in Parkinson's patients, particularly when they were not on medication, indicating its potential as a therapeutic intervention for motor symptoms in Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Akinesia in Parkinson's disease. II. Effects of subthreshold repetitive transcranial motor cortex stimulation. Pascual-Leone, A., Valls-Solé, J., Brasil-Neto, JP., et al.[2019]

In a study involving 22 patients with Parkinson's disease, various rTMS protocols were tested over 5 days, but none showed significant improvement over placebo in enhancing motor function.

The only notable result was in the Purdue Pegboard Test, where all active rTMS protocols performed slightly better than sham stimulation, indicating that while rTMS may have some effects, motor training and medication likely played a larger role in observed improvements.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Training effects outweigh effects of single-session conventional rTMS and theta burst stimulation in PD patients. Rothkegel, H., Sommer, M., Rammsayer, T., et al.[2019]

Repetitive transcranial magnetic stimulation (rTMS) significantly reduced depression scores in Parkinson's disease patients, showing lasting effects even two weeks after treatment ended, indicating its potential as an effective antidepressant intervention.

The study involved 8 patients with Parkinson's disease and demonstrated that rTMS is a safe and painless method for alleviating depressive symptoms, which is crucial given the limitations of traditional antidepressant medications in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Effect of slow repetitive transcranial magnetic stimulation on depression in patients with Parkinson 's disease]. Potrebić, A., Dragasević, N., Svetel, M., et al.[2009]

Patients with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) exhibit motor cortex disinhibition, characterized by larger response amplitudes and reduced intracortical inhibition during transcranial magnetic stimulation (TMS).

In contrast, patients with corticobasal-ganglionic degeneration (CBGD) show hypoexcitability in the motor cortex, indicated by increased motor thresholds and smaller response amplitudes, suggesting more severe neuronal loss in this area.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes. Kühn, AA., Grosse, P., Holtz, K., et al.[2008]

Repetitive transcranial magnetic stimulation (rTMS) significantly reduced depression scores in Parkinson's disease patients, showing lasting effects even two weeks after treatment ended, indicating its potential as an effective antidepressant intervention.

The study involved 8 patients with Parkinson's disease and demonstrated that rTMS is a safe and painless method, with no significant changes in Parkinson's symptoms, highlighting its suitability for managing depression in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Effect of slow repetitive transcranial magnetic stimulation on depression in patients with Parkinson disease]. Potrebić, A., Dragasević, N., Svetel, M., et al.[2009]

In a study involving 26 patients with mild to moderate Parkinson's disease, 50-Hz repetitive transcranial magnetic stimulation (rTMS) was found to be safe, with no adverse effects or increased risk of cortical excitability.

However, the treatment did not lead to significant improvements in motor symptoms such as gait and bradykinesia, although there was a brief improvement in daily living activities, suggesting that longer or different rTMS protocols may be needed for better efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Controlled study of 50-Hz repetitive transcranial magnetic stimulation for the treatment of Parkinson disease. Benninger, DH., Iseki, K., Kranick, S., et al.[2021]

Repetitive transcranial magnetic stimulation (rTMS), particularly at 5 Hz over the supplementary motor area, has been shown to effectively improve motor symptoms in Parkinson's disease, as demonstrated in multiple randomized, double-blind, sham-controlled studies conducted in Japan.

The mechanism of action for rTMS involves normalizing excitability in the supplementary motor area, which may help restore function in the basal ganglia, and ongoing phase III trials suggest that rTMS could soon be a standard treatment option for Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Repetitive Transcranial Magnetic Stimulation for Parkinson's Disease: A Review]. Matsumoto, H., Ugawa, Y.[2017]

High-frequency repetitive transcranial magnetic stimulation (rTMS) significantly improved motor symptoms in 21 patients with Parkinson's disease, as measured by various scales including the Unified Parkinson's Disease Rating Scale (UPDRS-III) and walking tests.

However, rTMS did not show significant effects on non-motor symptoms like depression and apathy, and daily sessions did not provide additional benefits over a single session, indicating that while rTMS is effective for motor symptoms, its impact on non-motor symptoms remains limited.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson's disease. Maruo, T., Hosomi, K., Shimokawa, T., et al.[2016]

Transcranial magnetic stimulation (TMS) is safe to use with implanted deep brain stimulation (DBS) devices at low to moderate intensities, as no movement or temperature increase was observed during stimulation at 0.2 Hz with 100% intensity for 1 hour.

However, caution is advised when using high-intensity TMS (over 50%) near looped DBS leads, as it can exceed the safety limit for charge density, potentially leading to electrical tissue injury.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The safety of transcranial magnetic stimulation with deep brain stimulation instruments. Shimojima, Y., Morita, H., Nishikawa, N., et al.[2010]

Repetitive transcranial magnetic stimulation (rTMS) has shown long-lasting efficacy in treating Parkinson's disease, based on two clinical trials focused on the supplementary motor area.

Animal studies and a meta-analysis support the effectiveness of high-frequency rTMS, indicating it could become a significant treatment option for various neurological and psychiatric disorders.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Repetitive transcranial magnetic stimulation (rTMS) therapy for Parkinson disease]. Shirota, Y.[2019]

In a study involving 27 patients with Parkinson's disease, repetitive deep transcranial magnetic stimulation (rDTMS) using H-coils was found to be safe, with no adverse events reported during 12 treatment sessions.

Patients experienced a significant improvement in motor symptoms, with an average reduction of 10.8 points on the motor UPDRS scale after treatment, indicating the potential efficacy of rDTMS as an add-on therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Excitatory deep repetitive transcranial magnetic stimulation with H-coil as add-on treatment of motor symptoms in Parkinson's disease: an open label, pilot study. Spagnolo, F., Volonté, MA., Fichera, M., et al.[2018]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9340539/

Efficacy of repetitive transcranial magnetic stimulation in ...

The results suggest that high-frequency of rTMS on primary motor cortex (M1) is effective in improving motor symptoms; while the dorsolateral ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8790062/

Effect of Theta Burst Stimulation-Patterned rTMS on Motor ...

Our study demonstrated that cTBS over the SMA could significantly improve the UPDRS-III score for PD patients in the “off,” not in the “on,” medicine state.

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06087926

NCT06087926 | Apathy in Parkinson Disease TMS Study

The goal of this clinical trial is to develop non-invasive brain stimulation targets for the treatment of apathy, or motivation problems, in Parkinson ...

4.

frontiersin.org

frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1627932/full

Comparative efficacy of different modalities of transcranial ...

The network meta-analysis indicates that both HF-rTMS and LF-rTMS may be considered as effective adjunctive therapy to improve depression in patients with PD.

5.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S1353802019302962

Transcranial magnetic stimulation improves cognition over ...

Active TMS improves global cognitive performance over time in patients with Parkinson's disease and MCI. · There is no significant difference between the active ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC3653978/

Safety of Transcranial Magnetic Stimulation in Parkinson's ...

We conclude that current TMS and rTMS protocols do not pose significant risks to PD patients. We would recommend that TMS users in this population follow the ...

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5540142/

Repetitive Transcranial Magnetic Stimulation (rTMS) ...

rTMS therapy in patients with Parkinson disease results in mild-to-moderate motor improvements and has the potential to be used as an adjunct therapy for the ...

8.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06734676

fMRI-guided Transcranial Magnetic Stimulation Treatment ...

This study aims to compare the efficacy of targeting the newly discovered SCAN versus traditional effector-specific networks in M1 using ...

9.

sciencedirect.com

sciencedirect.com/science/article/pii/S1388245725004596

50 Hz-Repetitive transcranial magnetic stimulation ...

The current 50 Hz-rTMS protocols modulate functional connectivity in PD patients, but not the power spectrum.

10.

my.clevelandclinic.org

my.clevelandclinic.org/health/treatments/17827-transcranial-magnetic-stimulation-tms

TMS (Transcranial Magnetic Stimulation): What It Is

Transcranial magnetic stimulation uses a magnet to influence brain electrical activity. It's effective in treating depression and other mental health ...